Brad Savall

Dr. Brad Savall is the Vice President and Head of Chemistry at Herophilus. He has over 20 years of experience in medicinal chemistry, including the design of molecules optimized for brain diseases. He began his career at Janssen (Johnson & Johnson) where he led multiple drug discovery programs that delivered several clinical candidates across neuroscience and immunology, including JNJ-54175446, the first-in-class brain-penetrant P2X7-receptor antagonist in development for major depressive disorder. Subsequently he served as the Associate Director of Drug Discovery at Sanford Burnham Prebys Medical Discovery Institute, leading medicinal chemistry and drug discovery efforts on multiple early and mid-stage drug discovery programs. Prior to joining Herophilus, Dr. Savall served as Director of Medicinal Chemistry at Plexium where he led efforts to leverage the company’s phenotypic screening platform to discover monovalent protein degraders.